C4 Therapeutics

CCCC

Market cap $246M

Overview Fund Activity

3.46 USD

+0.80

30.08%

At close Updated Sep 15, 2:08 PM EDT

1 day

30.08%

5 days

28.15%

1 month

40.65%

3 months

112.27%

6 months

65.55%

Year to date

-5.46%

1 year

-45.6%

5 years

-86.43%

10 years

-86.43%

About: C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Employees: 110

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

693% more call options, than puts

Call options by funds: $111K | Put options by funds: $14K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 32

11% less funds holding

Funds holding: 114 [Q1] → 101 (-13) [Q2]

13.24% less ownership

Funds ownership: 90.3% [Q1] → 77.06% (-13.24%) [Q2]

24% less capital invested

Capital invested by funds: $103M [Q1] → $78.2M (-$24.3M) [Q2]

33% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 39

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

73% upside

Avg. target

$7

102% upside

High target

$8

131% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Stephens & Co. Sudan Loganathan	$6	Overweight Upgraded	15 Sep 2025
Guggenheim Brad Canino	$8	Buy Initiated	4 Sep 2025

See Analyst Rankings

Financial journalist opinion

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA).

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada.

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

The Motley Fool

CCCC Revenue Drops 46%

CCCC Revenue Drops 46%

CCCC Revenue Drops 46%

Zacks Investment Research

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.26 per share a year ago.

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which Is Focused on Two Projects Within the KRAS Family Disciplined Capital Allocation Extends Runway to Mid-2027 WATERTOWN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the second quarter ended June 30, 2025, as well as business updates.

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerability in heavily pretreated multiple myeloma patients, with key data readouts expected in Q3 2025. Cost controls and restructuring have extended CCCC's cash runway into 2027, reducing dilution risk and supporting ongoing development and partnerships.

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

Zacks Investment Research

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One Patient With a Minimal Residual Disease Negative Complete Response ; 40% ORR Achieved at the 75 µ g Dose Level

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Zacks Investment Research

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

See News Rankings

Charts implemented using Lightweight Charts™